Cytomegalovirus retinitis and HIV: Case reviews from KwaZulu-Natal Province, South Africa by Hassan-Moosa, R et al.
843       October 2017, Vol. 107, No. 10
IN PRACTICE
Cytomegalovirus (CMV) is a common opportunistic infection and 
a significant contributor to visual loss in patients with advanced 
stage HIV.[1] CMV seropositivity in Africa, specifically in sub-
Saharan Africa, is highly endemic with reported seropositivity 
rates approaching 100%.[2] Despite antiretroviral therapy (ART), 
CMV infection in AIDS patients remains a significant risk factor 
for end organ disease and AIDS-related mortality.[3,4] Prior to the 
introduction of ART) 30 - 40% of HIV-infected individuals  developed 
CMV retinitis.[5] However, the introduction of ART has resulted in a 
precipitous decline in CMV retinitis infections, which is particularly 
evident in the developed world.[6] Reported prevalence rates of CMV 
retinitis in HIV-infected patients varied between <5% in South 
Africa (SA) to >30% in South East Asia,[7] with a study in Cape Town 
reporting a prevalence rate of 0.8% (p<0.001) in patients with CD4+ 
cell counts <200 µ/L.[8] Data on local incidence rates are limited with 
the literature reporting sub-Saharan African incidence rates of <10%.[9]
Resource-limited settings are challenged by inaccessibility of 
ocular care for HIV-infected patients on ART programmes, owing 
to a lack of skilled staff to conduct ophthalmic examinations. The 
mainstay of diagnosis of CMV retinitis is fundoscopy through a 
dilated pupil.[10] However, as CMV retinitis is asymptomatic in 
almost half of affected patients in the early stages of disease,[11] routine 
screening fundoscopy for those at high risk of CMV disease by a 
trained clinician, not necessarily an ophthalmologist, is necessary. 
A review of the data from a 3-year pilot programme in Myanmar[12] 
showed the feasibility of CMV retinitis management at primary care 
level in resource-poor settings. Like other HIV-associated major 
opportunistic infections, CMV retinitis was diagnosed and treated 
by AIDS clinicians (non-ophthalmologists), with the appropriate 
training and support, prompting calls for the WHO to include routine 
ophthalmoscopy for all patients presenting for ART initiation with low 
CD4+ cell counts (<100 cells/µL) in AIDS treatment guidelines.[4,12] 
CMV retinitis is a slow and progressive disease in patients with 
advanced stage HIV.[2] Initial symptoms include visual field defects, 
the visualisation of floaters, flashes and a decline in vision, which 
initially occurs in one eye.[13] The disease is diagnosed presumptively 
by means of fundoscopy, unlike systemic CMV disease, which requires 
confirmation by biopsy.[11] Characteristic findings on fundoscopy 
include dense retinal whitening, haemorrhage, and a typical ‘brush-
fire’ retinitis pattern that distributes along blood vessels with small 
white satellite lesions at the border.[2] CMV retinitis is commonly 
confused with HIV retinopathy; however, the latter fades and 
condenses over time while CMV retinitis progresses.[2] When left 
untreated, CMV retinitis can progress to retinal detachment with 
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Background. Retinal cytomegalovirus (CMV) infection is a common opportunistic infection and remains a significant contributor to 
visual loss in patients with AIDS. We highlight the poor outcomes of CMV retinitis in three HIV-infected patients who were initiated on 
antiretroviral therapy (ART). We conducted a retrospective chart review of advanced stage HIV-infected patients with known CMV retinitis.
Case 1. A 37-year-old man, with a CD4+ cell count of 35 cells/µL, presented for ART initiation with a 5-month history of visual loss in his 
left eye. Fundoscopy showed left eye CMV retinitis and right eye HIV retinopathy. ART and 5 months of weekly intravitreal ganciclovir 
injections (left eye) were commenced. Six-month outcomes included virological suppression, and visual acuity in the right eye of 6/6 and 
in the left eye of 3/60.
Case 2. A 31-year-old woman, with a CD4+ cell count of 39 cells/µL and on tuberculosis therapy, presented for ART initiation. She presented 
with a 2-month history of decreased visual acuity. Fundoscopy showed bilateral CMV retinitis, which was more pronounced in the left eye. 
ART and 8 months of intravitreal ganciclovir injections were commenced. Six-month outcomes included virological suppression and visual 
acuity in the right eye of 6/9, and in the left eye of 6/24. 
Case 3. A 29-year-old woman, with a CD4+ cell count of 24 cells/µL, who was on tuberculosis therapy and ART, complained of blurred 
vision at her 2-month ART follow-up visit. Fundoscopy showed bilateral retinal detachment secondary to CMV retinitis. While silicone oil 
tamponade and subsequent retinectomy successfully repaired the right eye, extensive damage rendered the left eye irreparable. Six-month 
outcomes included virological suppression, with 6/120 visual acuity in the right eye and complete blindness in the left eye. 
Conclusion. CMV retinitis causes debilitating, permanent sequelae, which is preventable by ART initiation at higher CD4+ cell counts. Despite 
achieving virological suppression, vision could not be completely restored in these patients, irrespective of the severity of CMV retinitis.
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direct damage to the macula or optic nerve, resulting in  permanent 
blindness.[2] Blindness caused by CMV retinitis is irreversible and can 
occur prior to complete retinal destruction, which was responsible 
for >90% of HIV-associated blindness in the pre-ART era.[2] 
A total of 1 815 patients were enrolled into the PEPFAR-funded 
CAPRISA AIDS Treatment Programme (CAT) at the eThekwini site 
in Durban, South Africa (SA) between June 2004 and August 2013. 
In this report, we highlight the three patients in this cohort who 
developed CMV retinitis.  
Approval for data collection and analysis for the CAT programme 
was obtained from the University of KwaZulu-Natal Biomedical 
Research Ethics Committee (ref. no. E248/05). 
Case reports
Case 1 
In June 2011, a 37-year-old man presented for ART initiation with a 
baseline CD4+ cell count of 35 cells/µL. He complained of a 5-month 
history of painless visual loss in the left eye. ART was commenced and 
he was referred to the ophthalmology clinic. Fundoscopy of the right 
eye showed a clear cornea, normal lens, a pink disc and cotton wool 
spots (Fig. 1), with a baseline visual acuity of 6/18. Poorer visual acuity 
of 3/60 was evident in the left eye, with fundoscopic examination 
showing dense retinal whitening and full-thickness necrosis (Fig. 2). 
A diagnosis of CMV retinitis in the left eye and HIV retinopathy in 
the right eye was concluded. Weekly intravitreal ganciclovir injections 
into the left eye were commenced, and maintained for a total of 
6 months. At 6 months post ART initiation, the patient’s CD4+ cell 
count was 63 cells/µL and his viral load was 42  copies/mL. His last 
ophthalmology report showed an improvement in visual acuity to 6/6 
with no other pathology in the right eye. No visual improvement was 
noted in the left eye; visual acuity remained static at 3/60. The patient 
remained clinically stable otherwise. 
Case 2 
A 31-year-old woman, who was on TB treatment, presented for ART 
initiation in June 2007 with a baseline CD4+ cell count of 39 cells/µL. 
She complained of a 2-month history of deteriorating vision in both 
eyes, with the left eye being worse than the right. She was referred 
to the ophthalmology clinic and fundoscopy showed pigmented 
keratic precipitates on the cornea and frosted branch angiitis in the 
left eye. Retinitis, angiitis and hyperaemic discs were observed in 
the right eye. Bilateral CMV retinitis was confirmed. The patient 
was initiated on intravitreal ganciclovir injections in both eyes, and 
she started ART 6 weeks later. She received ganciclovir injections 
for 8 months and the visual acuity in her right eye improved to 6/9, 
and in her left eye to 6/24. The patient maintained viral suppression 
and had increased CD4+ cell counts of 220 and 440 cells/µL at 6 and 
18 months, respectively.
Case 3 
A 29-year-old woman, who was on TB treatment, presented for 
ART initiation in October 2006 with a baseline CD4+ cell count of 
24 cells/µL. The patient complained of blurred vision at her 2-month 
ART follow-up visit, and was referred to the ophthalmology clinic. 
Decreased visual acuity and impaired peripheral vision with a bilateral 
hemianopia was noted. Furthermore, bilateral retinal detachment 
secondary to CMV retinitis was observed on fundoscopy. The right 
eye was repaired with silicone oil tamponade. However, owing 
to poor prognosis secondary to extensive damage from complete 
retinal detachment in the left eye, surgical repair was not an option. 
Retinectomy and a repeat silicone oil tamponade was performed on 
the right eye ten months later. She was blind in the left eye and had 
impaired vision in the right eye that did not resolve after right eye 
surgery. The patient remained clinically stable over 5 years of follow-
up and her last known CD4+ cell count was 479 cells/µL. 
Discussion
Case 1 presented with mixed ocular pathology. HIV retinopathy 
presents in 70% of patients with advanced stage HIV disease[14] 
and affects the posterior segment of the eye, as does CMV retinitis. 
HIV retinopathy is an occlusive microangiopathy,[15] which presents 
as cotton wool spots, telangiectasia, microaneurysms and retinal 
haemorrhages. Cotton wool spots are the only common clinical 
feature in both HIV retinopathy and CMV retinitis;[16] however, cotton 
wool spots associated with HIV retinopathy are usually superficial, 
smaller lesions that resolve within a few months.[16] Immediate visual 
loss may not occur with HIV retinopathy and most often patients 
are asymptomatic.[16] However, there may be significant damage to 
the retinal nerve fibre layer, deterioration in colour vision and visual 
field deficits.[6] HIV retinopathy is a risk factor for CMV retinitis 
prompting the recommendation for routine ophthalmic examination 
every 3 months in patients with HIV retinopathy.[17] It is hypothesised 
that the microvasculopathy associated with HIV retinopathy aids the 
transit of CMV-infected leukocytes across vessel walls. Data from the 
Longitudinal Studies of the Ocular Complications of AIDS (LSOCA) 
Fig. 2. Left eye fundoscopy (case 1) showing dense retinal whitening and full- 
thickness necrosis.
Fig. 1. Fundoscopy of the right eye (case 1) showing a clear cornea, normal 
lens, a pink disc and cotton spots.
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cohort[4] concluded that the presence of HIV retinopathy increased the 
risk of CMV retinitis (hazard ratio 11.6; 95% CI 3.3 - 40.2; p=0.0001).
It is important to note that other HIV-associated infectious causes 
of a retinitis such as varicella zoster virus, Toxoplasma gondii and 
choroidopathy caused by Pneumocystis carinii, should be excluded.[15] 
Cryptococcal ocular complications can manifest in patients with 
advanced stage HIV disease who develop cryptococcal meningitis 
and subsequent optic neuritis and papilloedema.[18] Ocular TB 
has been described in HIV-infected patients with disseminated TB 
affecting both the anterior and posterior segments of the eye with a 
variety of presentations that include: vitritis, retinal vasculitis, optic 
neuritis, choroiditis and choroidal tubercules.[6,19] Retinal toxicity 
secondary to ARTs, and to drugs used to treat commonly occurring 
HIV-associated comorbidities such as tuberculosis therapy, has 
been described in the literature. Didanosine, which was one of the 
earliest nucleoside reverse transcriptase inhibitors, resulted in retinal 
toxicity in patients initiated on ART,[20] and ritonavir- and efavirenz- 
induced retinal pigment eptheliopathy (RPE) initiating a ‘bull’s eye 
maculopathy’ have also been reported in the literature.[21,22] 
Owing to its cost-effectiveness, intravitreal ganciclovir injection 
is the current standard treatment in the SA public sector for active 
CMV retinitis infection,[23] even though systemic ganciclovir or 
valganciclovir therapy is standard of care in other countries as 
these drugs assist in the  prevention  of systemic dissemination 
and improving survival.[3,23] These injections are prescribed in 
combination with daily ART; the dose is based on clinical response 
and immune recovery and is stopped when CD4+ cell counts of 
>100 cells/µL are achieved.[24] The third case developed retinal 
detachment, which is a severe complication of CMV retinitis. Risk 
factors for retinal detachment include large anterior retinal lesions, 
intravitreal ganciclovir injections and bilateral disease.[25] While our 
patient demonstrated bilateral disease, she did not receive intravitreal 
injections, and we were unable to comment on the size of the anterior 
retinal lesion owing to the extent of the pathology on presentation.  
Retinal detachment is associated with poor visual outcomes 
leading to doubling of the visual angle and eventual blindness 
despite the initiation of ART, as was noted in our patient.[3,26] This 
patient reported an onset of visual loss post ART initiation and could 
have been a case of missed CMV retinitis at screening as she was 
asymptomatic. An important consideration in this patient would be 
an immune reconstitution inflammatory syndrome presenting as an 
immune recovery vitritis or immune recovery uveitis (IRU). IRU is 
a paradoxical worsening of intraocular inflammatory reactions that 
occurs during immune recovery after the administration of ART 
and can lead to substantial visual loss.[23] IRU can occur in 63% of 
patients with previous CMV retinitis[27] and can present as a mild 
decrease in vision with the presence of floaters, pain and redness in 
the affected eye.[28]
Untreated CMV retinitis can lead to permanent blindness as a 
result of direct damage to the macula or optic nerve, or owing to 
retinal detachment. The need for surgical management to treat 
complications such as retinal detachment is often delayed in 
resource-limited settings and the persistent threat of developing 
CMV infection with chronic virological, immunological and clinical 
failure remains. 
The three cases presented here highlight the severe and irreversible 
visual complications characteristic of CMV retinitis. Despite early 
identification and rapid referral to a tertiary ophthalmology service, 
all patients developed permanent and irreversible visual impairment. 
The greatest risk factor for active CMV retinitis infection is a CD4+ 
cell count of <50 cells/µL[4,29,30] in HIV infected patients, irrespective 
of whether patients are receiving ART. It is noteworthy that 90% 
of patients with incident CMV retinitis analysed in the LSOCA 
cohort[31] had a recent CD4+ cell count of <50 cells/µL, with 85% 
reporting ART use at the visit prior to CMV diagnosis.[4] 
The mainstay of CMV retinitis management is disease prevention 
through early ART initiation, especially before CD4+ cell count levels 
decline to <50 cells/µL. Furthermore, the importance of conducting 
routine ophthalmological examinations on patients presenting for 
ART initiation with advanced disease needs to be emphasised.[2,31,32] 
Visual loss adds to the overwhelming social and economic burden 
on patients and societies already plagued by HIV. We support the 
recommendation that routine fundoscopic examination be included 
in the standard WHO care package for HIV-infected patients with 
advanced disease.[10] Similar to other opportunistic infections in HIV, 
CMV screening, prevention, early diagnosis and treatment access 
should also be offered to patients at high risk for this complication. 
While all our patients presented with a history of visual loss, published 
data from elsewhere show high rates of asymptomatic CMV retinitis. 
Data from Myanmar showed that 31% of the 42 patients diagnosed 
with CMV retinitis by fundoscopy, were asymptomatic.[2] 
Asymptomatic CMV retinitis was also demonstrated in 44% of 
Cambodian patients, despite the use of a questionnaire designed 
specifically to elicit symptoms of CMV retinitis.[2] While studies 
advocate education of patients with low CD4+ cell counts 
(<100 cells/µL)[10] on the risk of CMV retinitis, and highlight 
the need for urgent medical evaluation in patients presenting 
with ophthalmic symptoms,[33] there are still large numbers of 
asymptomatic CMV retinitis cases. This underscores the need for 
the inclusion of routine fundoscopy in treatment guidelines for 
patients with advanced stage HIV as well as investment in training 
and infrastructure to enable frontline workers to conduct routine 
fundoscopic examinations on eligible patients. The training of non-
ophthalmologist clinicians in the use of telemedicine in screening 
for CMV retinitis, by means of digital fundus photography, should 
be explored.[34]
Study limitations
This was a retrospective data review and there was missing 
information with regard to ophthalmology visits and the relevant 
feedback reports. In addition, images for two of the cases reviewed 
here could not be retrieved from the ophthalmology department 
owing to technical errors with equipment.
Conclusion
CMV retinitis is a preventable condition that has debilitating and 
permanent sequelae. Our review highlights the importance of ART 
and diagnosing patients in the early stages of HIV infection, as well as 
the importance of routine ophthalmoscopy in patients with advanced 
stage disease. CMV retinitis frequently affects young individuals in 
the most productive stage of life. Despite virological suppression and 
immune recovery on ART, vision cannot be restored and blindness 
leads to a life of dependency in such cases.[2]  
CMV retinitis exists in the era of ART – we should not be lulled 
into believing otherwise. As we adopt the ‘test and treat’ strategy 
in SA, it is essential that frontline healthcare workers are trained 
in identifying CMV retinitis in high-risk individuals and that non-
ophthalmologist clinicians are equipped with the necessary skills 
to conduct ophthalmological examinations as part of routine HIV 
care. Furthermore, routine ophthalmological screening should be 
incorporated into standard treatment guidelines and algorithms for 
patients with CD4+ cell counts <100 cells/µL. 
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